[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cisplatin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cisplatin":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100053935","phase-2-steroid-sparing-regimen-with-olanzapine-and-palonosetron-for-emetic-prevention-for-high-dose-cisplatin-100053935",false,"NCT07699276","Steroid Sparing Regimen With Olanzapine and Palonosetron for Emetic Prevention for High Dose Cisplatin","Steroid-sparing Regimen With Olanzapine and Ondansetron to Prevent Emesis Caused by High Dose Cisplatin in Solid Cancer Patient : A Single Arm Phase II Study","Inclusion Criteria:\n\n* histologically confirmed solid malignancy\n* scheduled for first cycle of cisplatin at dosage of at least 50 mg\u002Fm2\n\nExclusion Criteria:\n\n* pregnancy\n* pelvic or abdominal radiation within 4 weeks\n* uncontrolled brain metastasis\n* other moderate or high emetic risk chemotherapy on day 2-5\n* untreated gut obstruction\n* known allergy or severe adverse effect from palonosetron or olanzapine\n* AST\u002F ALT \\> 2.5x or serum creatinine clearance less than 50 ml\u002Fmin","ALL","18 Years",{"count":19,"type":20},95,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","A phase II study evaluating dexamethasone sparing regimen with olanzapine and palonosetron for patients receiving high dose cisplatin to prevent chemotherapy induced nausea and vomiting",[26,27,28,29],"Cancer (Solid Tumors)","Vomiting","Cisplatin","Olanzapine",[31,32,33,34],"cisplatin","chemotherapy induced nausea vomiting","dexamethasone sparing","olanzapine","RECRUITING","2026-07-07",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":39},"2026-02-10",{"date":43,"type":20},"2027-11-15",{"name":45,"class":46},"Mahidol University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":67,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100589912","phase-3-perioperative-durvalumab-with-neoadjuvant-ddmvac-or-gemcitabinecisplatin-in-patients-with-muscle-invasive-bladder-cancer-niagara-2-100589912","NCT06960577","Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine\u002FCisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)","A Phase IIIb, Open-label, Single-arm, Global Study of Perioperative Durvalumab With Neoadjuvant ddMVAC or Gem\u002FCis in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)","Inclusion Criteria:\n\n* Participants with clinical tumour stage T2-T4aN0\u002F1M0 or T1N1M0 with transitional or mixed transitional cell histology\n* Patients must be planning to undergo radical cystectomy\n* Patients who have not received prior systemic chemotherapy or immunotherapy for treatment of muscle-invasive bladder cancer\n* ECOG performance status of 0 or 1\n* Minimum life expectancy of 12 weeks at first dose of study medication\n\nExclusion criteria:\n\n* Evidence of lymph node (N2-N3) or metastatic (M1) disease\n* Inoperable tumour(s) with fixation to the pelvic wall on clinical examination\n* Prior exposure to immune-mediated therapy including, but not limited to, other anti CTLA-4, anti-PD 1, anti-PD L1 and anti-PD-L2 antibodies, excluding Bacillus Calmette-Guérin\n* Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab\n* Any concomitant medication known to be contraindicated to the chemotherapy (ddMVAC or gem\u002Fcis).\n* Uncontrolled intercurrent illness.",{"count":56,"type":20},150,[58],"PHASE3","The Phase IIIb NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with investigator-selected cisplatin-based neoadjuvant chemotherapy (either ddMVAC or gemcitabine\u002Fcisplatin) in a clinical practice setting.",[61,62,63,64,65,28,66],"Urinary Bladder Neoplasms","Immune Checkpoint Inhibitors","Methotrexate","Vinblastine","Doxorubicin","Gemcitabine",[68,69,70,71,72,73,66,28],"Muscle-invasive Bladder Cancer","Bladder Cancer","Immunotherapy","Durvalumab","Perioperative Durvalumab","ddMVAC","2026-06-10",{"date":76,"type":39},"2026-06-11",{"date":78,"type":39},"2025-05-15",{"date":80,"type":20},"2028-10-31",{"name":82,"class":83},"AstraZeneca","INDUSTRY",59,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":21,"phases":95,"briefSummary":96,"conditions":97,"keywords":100,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":47},"100356327","phase-3-cisplatin-based-and-carboplatin-based-chemoradiation-in-locoregionally-advanced-nasopharyngeal-carcinoma-100356327","NCT03919552","Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma","Intensity-modulated Radiation Therapy Combined With Cisplatin-based or Carboplatin-based Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma：: A Phase 3 Trial","Inclusion Criteria:\n\n* Patients with newly histologically confirmed non-keratinizing (according to World Health Organization (WHO) histologically type).\n* Tumor staged as T3-4Nx\u002FTxN2-3 (according to the 8th American Joint Commission on Cancer edition).\n* No evidence of distant metastasis (M0).\n* Satisfactory performance status: Karnofsky scale (KPS) \\> 70.\n* Adequate marrow: leucocyte count ≥4000\u002FμL, hemoglobin ≥90g\u002FL and platelet count ≥100000\u002FμL.\n* Normal liver function test: Alanine Aminotransferase (ALT)、Aspartate Aminotransferase (AST) \\\u003C1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP) ≤2.5×ULN, and bilirubin ≤ULN.\n* Adequate renal function: creatinine clearance ≥60 ml\u002Fmin.\n* Patients must be informed of the investigational nature of this study and give written informed consent.\n\nExclusion Criteria:\n\n* WHO Type keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma.\n* Age ≥65 years or \\\u003C18 years.\n* Treatment with palliative intent.\n* Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer.\n* Pregnancy or lactation.\n* History of previous radiotherapy (except for non-melanomatous skin cancers outside intended RT treatment volume).\n* Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes.\n* Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose \\>1.5×ULN), and emotional disturbance.","64 Years",{"count":94,"type":20},482,[58],"The purpose of this study is to compare cisplatin-based with carboplatin-based chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma (NPC), in order to confirm the value of carboplatin-based chemoradiotherapy in NPC patients.",[28,98,99],"Carboplatin","NPC",[101,31,102],"Nasopharyngeal Carcinoma","carboplatin","2023-06-14",{"date":105,"type":39},"2023-06-18",{"date":107,"type":39},"2018-01-31",{"date":109,"type":20},"2026-12-31",{"name":111,"class":46},"Nanfang Hospital, Southern Medical University"]